(Q73002226)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11005266%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

title

A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11005266%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author

Daniel Antonio de Luis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11005266%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

José I Botella-Carretero

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11005266%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

A Becerra

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11005266%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

M Lahera

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11005266%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Valero

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11005266%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

C Varela

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11005266%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 July 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11005266%20AND%20SRC:MED&resulttype=core&format=json

Journal of Endocrinological Investigation

31 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11005266%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11005266%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11005266%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

428-434

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11005266%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf03343751

31 October 2019

exact match

0 references

cites work

Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502

1 reference

12 December 2020

Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment

1 reference

12 December 2020

Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group.

1 reference

12 December 2020

CV 205-502 treatment of hyperprolactinemia

1 reference

12 December 2020

A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia

1 reference

12 December 2020

The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine.

1 reference

12 December 2020

CV 205–502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia

1 reference

12 December 2020

Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine

1 reference

12 December 2020

Drugs five years later. Bromocriptine

1 reference

12 December 2020

Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients

1 reference

12 December 2020

Dopaminergic treatments for hyperprolactinaemia

1 reference

12 December 2020

Parenteral bromocriptine in the treatment of hormonally active pituitary tumours

1 reference

12 December 2020

LHRH-induced gonadotropin release before and after short-term therapy with cabergoline in hyperprolactinaemic patients

1 reference

12 December 2020

Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients

1 reference

12 December 2020

Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study

1 reference

12 December 2020

A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients

1 reference

12 December 2020

Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline

1 reference

12 December 2020

Cabergoline: long-acting oral treatment of hyperprolactinemic disorders

1 reference

12 December 2020

Hormonal effects of CV 205-502, a novel octahydrobenzo [g] quinoline with potent dopamine agonist properties

1 reference

12 December 2020

A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.

1 reference

12 December 2020

Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas

1 reference

12 December 2020